Advertisement Actavis introduces Namzaric in US to treat moderate to severe Alzheimer's disease - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Actavis introduces Namzaric in US to treat moderate to severe Alzheimer’s disease

Irish over-the-counter (OTC) firm Actavis has launched Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) in the US to treat moderate to severe Alzheimer's disease (AD).

Namzaric is a once-daily, fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist), and donepezil hydrochloride (an acetylcholinesterase inhibitor).

Last December, the US Food and Drug Administration (FDA) approved Namzaric to treat moderate to severe AD in patients stabilized on memantine hydrochloride and donepezil hydrochloride.

Namzaric will be available in two dosage strengths, 28/10mg (memantine HCl extended-release/donepezil HCl) and 14/10mg (memantine HCl extended-release/donepezil HCl) for patients with severe renal impairment.

Actavis Branded Pharma president Bill Meury said: "We’re excited to make once-daily Namzaric available as another treatment option for patients with moderate to severe Alzheimer’s disease.

"Since the launch of Namenda XR (memantine hydrochloride) in 2013, the two medications, Namenda XR and donepezil, have been commonly prescribed in combination with one another to treat the symptoms of moderate to severe Alzheimer’s disease.

"Namzaric offers an option with the benefits of both treatments, while reducing the number of pills a patient and their caregivers need to administer each day, to treat this disease."

The company has jointly developed the fixed-dose combination in collaboration with Adamas Pharmaceuticals.

Under this deal, Actavis will have exclusive US commercialization rights of the product, while Adamas will retain exclusive commercialization rights outside of the US.